Opinion

Video

Future Directions in Combination Therapies for Myelofibrosis

Author(s):

Andrew Kuykendall, MD,Raajit K. Rampal, MD, PhD

Andrew Kuykendall, MD, and Raajit K. Rampal, MD, PhD, reflect on the future of combination therapies in treating myelofibrosis, emphasizing the need to align study endpoints with treatment goals and highlighting the potential of various combinations based on promising preclinical and early phase study results.

Related Videos
Justin M. Watts, MD
Michael R. Grunwald, MD, FACP
Minoo Battiwalla, MD, MS
Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.
Daniel DeAngelo, MD, PhD
Francine Foss, MD
Daniel DeAngelo, MD, PhD
Daniel DeAngelo MD, PhD, professor, medicine, Harvard Medical School; physician, chief, Division of Leukemia, Dana-Farber Cancer Institute
David C. Fisher, MD
Farrukh Awan, MD
Related Content
OncLive’s November Roundup of Key FDA Approvals in Oncology
December 3rd 2024

OncLive’s November Roundup of Key FDA Approvals in Oncology

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

Leo I. Gordon, MD
December 2nd 2024

Vice Chair of the B-Cell Lymphomas NCCN Guidelines Maps Critical Changes From 2024

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

OncLive's Top Stories of the Week
November 30th 2024

The OncFive: Top Oncology Articles for the Week of 11/24

Lori Muffly, MD
November 29th 2024

Obe-Cel Approval Expands CAR T-Cell Therapy Options in Relapsed/Refractory ALL